Brokerage firms are bullish on Afcons Infrastructure, Delhivery, and Piramal Pharma, projecting significant upside potential. Investec, Equirus, and JM Financial have initiated coverage with buy ratings, citing strong growth prospects, robust financials, and attractive valuations. These companies are poised for substantial gains, driven by infrastructure development, e-commerce growth, and pharmaceutical sector expansion.
